Exelixis achieves enrollment target for phase 3 trial of cabozantinib

theflyonthewall.com

Exelixis has reached the enrollment target of 960 patients for COMET-1, the company’s phase 3 pivotal trial of cabozantinib in patients with metastatic castration-resistant prostate cancer. The primary endpoint of COMET-1 is overall survival, and Exelixis continues to expect top-line data from COMET-1 and a second pivotal trial in mCRPC, COMET-2, in 2014.

Rates